Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NM-101
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Single Ascending Dose Study
Details : NM-101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 18, 2025
Lead Product(s) : NM-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NM-101
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NM-101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 30, 2023
Lead Product(s) : NM-101
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tomaralimab
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Collaboration
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
Details : Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : Tomaralimab
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Collaboration